GlucoRx and Cardiff University are set to bring out the world’s first non-invasive continuous glucose monitor (CGM) in what they say will herald a new era of needle-free monitoring for people with diabetes.
The GlucoRx BioXensor uses radio frequency technology alongside a multiple sensor approach to measure blood glucose levels every minute.
According to the World Health Organization, approximately 422 million people around the globe have diabetes.
Currently, people with diabetes must prick their finger to extract and test their blood several times a day using glucometers or apply semi-invasive devices such as continuous blood glucose monitors (CGMs).
The GlucoRx BioXensor now provides people with an alternative to blood glucose monitoring for the first time by measuring levels from 3mmol/l to 30 mmol/l.
The small and discreet wearable multi-sensor device weighs 14g and is 42mm in diameter by 7mm. It was developed in collaboration with Professor Adrian Porch and Dr Heungjae Choi, who are both experts in radio frequency technology from Cardiff University’s School of Engineering.
When used as an early intervention to change lifestyle, the GlucoRx BioXensor will assist in preventing the onset of diabetes, or its remission, and improve quality of life with its smart alarms and remote monitoring technology.
Chris Chapman, GlucoRx chief operating officer, said: “We are exciting about this life-changing end-to-end diabetes monitoring platform of ours which can be discreetly stuck on the skin to monitor blood glucose, giving readings every minute on smart mobile applications.
“GlucoRx BioXensor has standout accuracy with a proven MARD of 10.4%, owing to its multi sensor approach capturing blood glucose as well as Sp02, ECG, respiration rate, heart rate, temperature, activity, sleep, and early fall detection. The wearable device has a longer shelf-life because it is not chemical in its action.”
Following a series of successful trials at Swansea University with Professor Stephen Luzio, the team is said to conduct a further pivotal clinical study later this year on its smaller and improved fourth generation device before submitting CE certification.
